Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. GPIHBP1 autoantibody syndrome during interferon β1a treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. ANGPTL4 inactivates lipoprotein lipase by catalyzing the irreversible unfolding of LPL's hydrolase domain

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The PCNA interaction motifs revisited: thinking outside the PIP-box

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Ambika P Ashraf
  • Kazuya Miyashita
  • Katsuyuki Nakajima
  • Masami Murakami
  • Robert A Hegele
  • Michael Ploug
  • Loren G Fong
  • Stephen G Young
  • Anne P Beigneux
View graph of relations

Chylomicronemia caused by a deficiency in lipoprotein lipase (LPL) or GPIHBP1 (the endothelial cell protein that transports LPL to the capillary lumen) is typically diagnosed during childhood and represents a serious, lifelong medical problem. Affected patients have high plasma triglyceride levels (>1500 mg/dL) and a high risk of acute pancreatitis. However, chylomicronemia frequently presents later in life in the absence of an obvious monogenic cause. In these cases, the etiology for the chylomicronemia is presumed to be "multifactorial" (involving diabetes, drugs, alcohol, or polygenic factors), but on a practical level, the underlying cause generally remains a mystery. Here, we describe a 15-year-old female with chylomicronemia caused by GPIHBP1 autoantibodies (which abolish LPL transport to the capillary lumen). Remarkably, chylomicronemia in this patient was intermittent, interspersed between periods when the plasma triglyceride levels were normal. GPIHBP1 autoantibodies were easily detectable during episodes of chylomicronemia but were undetectable during periods of normotriglyceridemia. During the episodes of chylomicronemia (when GPIHBP1 autoantibodies were present), plasma LPL levels were low, consistent with impaired LPL transport into capillaries. During periods of normotriglyceridemia, when GPIHBP1 autoantibodies were absent, plasma LPL levels normalized. Because the chylomicronemia in this patient was accompanied by debilitating episodes of acute pancreatitis, the patient was ultimately treated with immunosuppressive drugs, which resulted in disappearance of GPIHBP1 autoantibodies and normalization of plasma triglyceride levels. GPIHBP1 autoantibodies need to be considered in patients who present with unexplained acquired cases of chylomicronemia.

Original languageEnglish
JournalJournal of Clinical Lipidology
Volume14
Issue number2
Pages (from-to)197-200
Number of pages4
ISSN1933-2874
DOIs
Publication statusPublished - 29 Feb 2020

ID: 59783166